What Narasimhan said on TV
On Bloomberg Television Friday, Vas Narasimhan cautioned that "The current approach would limit our ability to bring these technologies into our US factories for US patients and vice versa, US into China," and added he is "hoping more sensible approaches will come out of these discussions." He also said, "Finding a new treatment for cancer or heart disease is not a national security issue," and that breakthroughs should be available to patients in China and the US.
What the proposals would do
The Treasury Department last month moved to include biotechnology on the list of sensitive technologies facing investment limits with foreign adversaries. That would broaden a program created under the Comprehensive Outbound Investment National Security, or COINS, Act, which already targets artificial intelligence, semiconductors and quantum computing. Multinational drugmakers with US staff or operations, including Switzerland based Novartis, could fall under the rules.
Why it matters for drugmakers and your portfolio
For Western drugmakers like Novartis, their foremost commercial arena is the US, while China ranks No. 2 and is playing a growing role in supplying new medicines and technologies. Restrictions on cross-border biotech collaboration could hinder R&D and make it harder to reach the most critical markets. It is also part of a wider US push to curb China's biotech advances, following last year's Biosecure Act that restricts federal agencies and government funded companies from using services from certain Chinese biotech firms, albeit in a narrower form than first proposed.
Policy debates often affect long term planning, so get clear context every morning from the free Market Briefs
The bottom line for investors
If these US restrictions advance, they could slow the creation of new drugs and make it tougher for companies to access key markets like the US and China.
When developments span medicine, tech and trade, stay on top with our concise free Market Briefs newsletter each day
